ABP-206

nivolumab biosimilar · Amgen

Drug timelines are a Plus or Pro feature.

2 regulatory and trial events tracked for ABP-206, covering 2026-01-12 to 2026-03-27. Get the full timeline:

Most recent: Clinical Trial Update: A Study to Evaluate Similarity of ABP 206 Compared With OPDIVO® (Nivolumab) in Subjects With Resected Melanoma [Phase 3]

See pricing